US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,833.20

-2.0856-0.11%

Number of Gainers:2

Number of Losers:17

Number of Flat:- -

PE:- -

High:1,844.83

Open:1,843.77

Low:1,825.88

Close:1,835.29

Volume:67.37M

Turnover:3.35B

Market Cap:1.49T

Float Cap:1.46T

Loading ...

Opus Genetics price target raised to $16 from $13 at Chardan

TwoStep Therapeutics Raises $62.5 Million in Series a Led by Insight Partners, Medical Excellence Capital

Moderna Set for 3 Near-Term INT Data Readouts, UBS Says

MT Newswires Live

AstraZeneca Shares Look Set for Swift Recovery

AstraZeneca's COPD Drug Data to Boost Sales Outlook

RBC Initiates AstraZeneca at Outperform With GBP145 Price Target

MT Newswires Live

BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating

MT Newswires Live

Ocugen to Share Ophthalmic Gene Therapy Progress

NYSE Most Active Issues

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Pfizer Inc. Stock Underperforms Tuesday When Compared to Competitors

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Abbott Laboratories Stock Underperforms Tuesday When Compared to Competitors

BioNTech CEO Ugur Sahin Sells Ordinary Shares Worth $7.86 Million

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS

Moderately bullish activity in Moderna with shares down 1.79%

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK4568/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1833.2035,"timestamp":1789069258140,"preClose":1835.2891,"halted":0,"volume":67373510,"delay":0,"changeRate":-0.001136,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-2.085571,"latestTime":"09-10 15:40:58 EDT","open":1843.7695,"high":1844.8345,"low":1825.875,"amount":3352556700.341715,"amplitude":0.010331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.81388,"peRate":46.873968,"turnoverRate":0.004856,"increases":2,"decrements":17,"flats":0,"marketCap":1491220616460.5,"floatMarketCap":1457423706882},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1844.8345,"amplitude":0.010331,"preClose":1835.2891,"low":1825.875,"pbRate":"4.81388","latestPrice":1833.201,"volume":67372139,"delay":0,"open":1843.7695,"prevYearClose":1637.1339,"prevWeekClose":1896.2245,"prevMonthClose":1860.7577,"prevQuarterClose":1731.2963,"fiveDayClose":1903.6779,"twentyDayClose":1769.2863,"sixtyDayClose":1652.1289,"secType":"PLATE","market":"US","turnoverRate":0.004856,"peRate":46.873968,"marketCap":1491220616460.5,"floatMarketCap":1457423706882,"timestamp":1789069257265,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":2,"down":17,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666329645","title":"Opus Genetics price target raised to $16 from $13 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2666329645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666329645?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:40","pubTimestamp":1788975649,"startTime":"0","endTime":"0","summary":"Chardan analyst Andreas Argyrides raised the firm’s price target on Opus Genetics (IRD) to $16 from $13 and keeps a Buy rating on the shares follow...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-raised-to-16-from-13-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-raised-to-16-from-13-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BNTX","BK4568","BK4535","BK4585","BK4551","IRD","BK4588","BK4548","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532336","title":"TwoStep Therapeutics Raises $62.5 Million in Series a Led by Insight Partners, Medical Excellence Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532336","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666532336?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:38","pubTimestamp":1788975520,"startTime":"0","endTime":"0","summary":"TwoStep Therapeutics raises $62.5 million in Series A led by Insight Partners, Medical Excellence CapitalTwoStep Therapeutics raised a USD 62.5 million oversubscribed Series A led by Insight Partners,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL44Fpct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LU1023059063.AUD","LU1057294990.SGD","SG9999002224.SGD","SG9999002232.USD","SG9999003800.SGD","LU0321505868.SGD","BK4581","BK4550","LU1066053197.SGD","LU0868494617.USD","LU1883839398.USD","BK4592","LU1894683264.USD","BK4533","LU0289739699.SGD","IE00BLSP4452.SGD","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","IE00B19Z3B42.SGD","SG9999011175.SGD","LU0321505439.SGD","SG9999013999.USD","BK4588","LU0234572021.USD","OZEM","LU1066051498.USD","BK4599","LU0985481810.HKD","BK4007","LU2596442595.SGD","BK4585","IE00BLSP4239.USD","BK4534","IE00B19Z3581.USD","SG9999001176.SGD","LU0306806265.USD","IE00B3T34201.USD","BK4568","LU0456855351.SGD","LU0170899867.USD","LU0306807586.USD","SGXZ57979304.SGD","PFE","LU0058720904.USD","IE0002270589.USD","LU0225284248.USD","IE000M9KFDE8.USD","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666311265","title":"Moderna Set for 3 Near-Term INT Data Readouts, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666311265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666311265?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:58","pubTimestamp":1788969505,"startTime":"0","endTime":"0","summary":"Moderna  is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Securities said in a Tuesday note.The next major catalyst is the release of phase 3 data on melanoma at an international conference this fall, investors awaiting efficacy on recurrence-free survival and distant metastasis-free survival, the brokerage said.Likely to follow is the phase 2 data on either renal cell carcinoma or muscle-invasive bladder cancer, potentially in 2027, according to UBS. The next readout is probably a phase 3 update on adjuvant non-small cell lung cancer, the investment firm added.UBS has a neutral rating and $150 price target on Moderna.Price: 137.50, Change: -2.83, Percent Change: -2.02","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MRNX","BK4139","BK4568","BK4501","BK4585","MRNA","BK4588","LGHT","GNOM","IDNA","BK4551","MRNY","BK4548","BK4534","WDNA","BK4533","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666362775","title":"AstraZeneca Shares Look Set for Swift Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2666362775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666362775?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:01","pubTimestamp":1788962460,"startTime":"0","endTime":"0","summary":"1401 GMT - AstraZeneca shares have been overly punished by recent concerns, but they look set for a swift recovery once uncertainty dissipates, RBC Capital Markets analysts say in a research note. The failure of a heart-disease clinical trial, takeover speculation and uncertainty about upcoming results from two big cancer studies have all weighed on the U.K. drugmaker's stock, the analysts say. AstraZeneca faces low expectations for the two late-stage trials in breast and lung cancers and it doesn't need them to be successful to reach its target of $80 billion in revenue by 2030, but uncertainty might keep risk-averse investors on the sidelines, they add. RBC starts coverage of AstraZeneca with an outperform recommendation and a target price of 145 pounds. Shares fall 1.7% to 116.82 pounds.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443549.SGD","LU0432979614.USD","LU1267930573.SGD","LU2237443465.HKD","LU2089984988.USD","LU1829250122.USD","LU2237443382.USD","LU2237443895.HKD","LU2236285917.USD","BK4568","LU0128525929.USD","LU0320765992.SGD","LU0310800379.SGD","AZN","LU2417539215.USD","BK4588","LU0889565916.HKD","LU0058720904.USD","LU0708994859.HKD","LU2468319806.SGD","AZNH","LU2237443978.SGD","LU2462157665.USD","LU0289739699.SGD","BK4007","LU2456880835.USD","LU2237443622.USD","LU0029864427.USD","LU0109394709.USD","BK4585","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666872533","title":"AstraZeneca's COPD Drug Data to Boost Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2666872533","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666872533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:29","pubTimestamp":1788956940,"startTime":"0","endTime":"0","summary":"1228 GMT - AstraZeneca reported blowout data for its new chronic obstructive pulmonary disease drug, which support sales expectations sharply above current consensus estimates, Citi analysts say in a research note. Full study results from the U.K. pharmaceutical company for its tozorakimab point to potential for a broad use across all populations of COPD patients, the analysts say. Tozorakimab also achieved better data for the subgroup of patients for which Sanofi and Regeneron's Dupixent and GSK's Nucala are approved, they add. As a result, Citi says the data support potential peak sales for tozorakimab of at least its estimate of $7 billion, or roughly double what the current consensus estimate for the drug projects. AstraZeneca shares fall 1.1%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AstraZeneca's COPD Drug Data to Boost Sales Outlook","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0432979614.USD","IE00B3T34201.USD","LU1829250122.USD","LU2236285917.USD","LU0109394709.USD","LU2468319806.SGD","LU0708994859.HKD","AZNH","LU0058720904.USD","LU1267930573.SGD","BK4588","LU2462157665.USD","LU2237443549.SGD","LU2237443622.USD","LU2237443895.HKD","LU0889565916.HKD","LU0029864427.USD","LU2237443978.SGD","LU0310800379.SGD","LU2237443382.USD","LU0320765992.SGD","LU0128525929.USD","LU2237443465.HKD","LU2456880835.USD","AZN","BK4007","LU0289739699.SGD","BK4585","BK4568","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666842995","title":"RBC Initiates AstraZeneca at Outperform With GBP145 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666842995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666842995?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:23","pubTimestamp":1788949437,"startTime":"0","endTime":"0","summary":"AstraZeneca's (AZN) London stock has an average rating of buy and mean price target of GBP160.21, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AZN","LU0708994859.HKD","LU2237443382.USD","LU0029864427.USD","LU0310800379.SGD","LU2237443895.HKD","LU0320765992.SGD","LU0058720904.USD","LU2089984988.USD","LU1267930573.SGD","BK4007","BK4585","LU2237443465.HKD","LU2468319806.SGD","LU1829250122.USD","LU2417539215.USD","BK4588","LU2456880835.USD","LU0889565916.HKD","LU0289739699.SGD","LU2462157665.USD","LU0432979614.USD","AZNH","LU2237443978.SGD","LU2237443549.SGD","BK4568","LU0128525929.USD","LU2236285917.USD","LU2237443622.USD","LU0109394709.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589690","title":"BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589690","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589690?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:19","pubTimestamp":1788945566,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) has an average rating of hold and mean price target of $28.49, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","BK4568","SG9999002232.USD","IE00BLSP4239.USD","LU0289739699.SGD","BK4550","IE0002270589.USD","IE00B3T34201.USD","LU1894683348.USD","IE00BLSP4452.SGD","BK4585","IE00B19Z3B42.SGD","BK4533","LU1066051498.USD","BK4588","LU1894683264.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0306807586.USD","LU0985481810.HKD","LU1883839398.USD","LU0306806265.USD","LU0058720904.USD","SG9999003800.SGD","BK4581","IE00B19Z3581.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999011175.SGD","BK4592","LU0321505439.SGD","LU0225771236.USD","LU2596442595.SGD","LU0456855351.SGD","BK4007","LU1023059063.AUD","LU0225284248.USD","SG9999001176.SGD","SG9999002224.SGD","IE00BBT3K403.USD","LU0122379950.USD","BK4534","LU0170899867.USD","LU0234572021.USD","OZEM","PFE","LU1057294990.SGD","BK4599","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308355","title":"Ocugen to Share Ophthalmic Gene Therapy Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308355","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308355?lang=en_us&edition=fundamental","pubTime":"2026-09-09 06:09","pubTimestamp":1788905392,"startTime":"0","endTime":"0","summary":"Ocugen ( ($OCGN) ) has shared an update. On September 8, 2026, Ocugen said it would publish an investor presentation outlining progress across its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ocugen-to-share-ophthalmic-gene-therapy-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ocugen-to-share-ophthalmic-gene-therapy-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","BK4563","BK4097","LU2065732104.USD","OCGN","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370245","title":"NYSE Most Active Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370245","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370245?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:43","pubTimestamp":1788903780,"startTime":"0","endTime":"0","summary":"Nu Holdings Cl A              NU    75,335,800     15.33    -0.04     -0.26. Nike Cl B                    NKE    31,566,287     38.10    -0.30     -0.78. BitMine Immersion Techs     BMNR    29,779,269     24.77    -0.20     -0.80. Petroleo Brasileiro ADR      PBR    28,786,500     20.83     0.71      3.53","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAPH","SG9999002232.USD","SG9999003800.SGD","BK4505","BK4585","IE00BLSP4239.USD","LU0170899867.USD","LU1057294990.SGD","BK4547","LU0058720904.USD","PFE","IE00B19Z3581.USD","LU2596442595.SGD","AADR","BK4604","LU0225284248.USD","APIE","IE00B3T34201.USD","BK4533","LU0321505439.SGD","DINT","DIVL","IE00B19Z3B42.SGD","OZEM","SG9999002224.SGD","AMC","SG9999001176.USD","BK4543","IE000M9KFDE8.USD","LU1861559042.SGD","CVY","LU0456855351.SGD","SGXZ57979304.SGD","JOBX","BK4008","JOBC","IE00BBT3K403.USD","ARMH","JOBY","LU0868494617.USD","BK4603","SG9999011175.SGD","LU1894683264.USD","PATX","BK4599","IE0002270589.USD","BK4592","BK4568","PATH","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377026","title":"Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377026","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377026?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:49","pubTimestamp":1788900540,"startTime":"0","endTime":"0","summary":"Assembly Biosciences said it exercised a profit-sharing option for the development of a herpes treatment under its collaboration agreement with Gilead Sciences.The biotechnology company said it will s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","BBH","TMED","ASMB","LU1066051498.USD","IBB","BK4139","IE00BSNM7G36.USD","BK4532","BK4583","LU0234570918.USD","SG9999015945.SGD","BK4550","LU0823416689.USD","LU0109394709.USD","BIB","LU0889565916.HKD","LU0965509101.SGD","LU1674673428.USD","LU1674673691.USD","GILD","LU1061106388.HKD","MEDI","TBXU","LU0320765992.SGD","LU2324357040.USD","LU2087621335.USD","IE00B3T34201.USD","LU1037948897.HKD","BK4588","BK4568","IE00BKVL7J92.USD","LU1057294990.SGD","IBBQ","LU0122379950.USD","LU0859254822.USD","BMED","LU0861579265.USD","LU1037948541.HKD","LU1839511570.USD","SG9999015978.USD","LU1585245621.USD","LU0058720904.USD","LU1066053197.SGD","LU2468319806.SGD","SG9999015952.SGD","LU0965508806.USD","IE0002270589.USD","BK4566","LU2357627491.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666217377","title":"Pfizer Inc. Stock Underperforms Tuesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666217377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666217377?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:36","pubTimestamp":1788899760,"startTime":"0","endTime":"0","summary":"DJ Pfizer Inc. Stock Underperforms Tuesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Pfizer Inc.  slid 2.32% to $27.79 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.58% to 7,673.52 and Dow Jones Industrial Average  falling 1.18% to 52,786.07.This was the stock's third consecutive day of losses.Pfizer Inc. closed 4.86% short of its 52-week high of $29.21, which the company achieved on September 3rd.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 2.22% to $269.12, Eli Lilly & Co.  fell 2.21% to $1,123.91, and Abbott Laboratories  fell 2.59% to $105.52.Data source: Dow Jones Market Data, FactSet. Data compiled September 8, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","IE00BLSP4239.USD","LU0122379950.USD","LU1023059063.AUD","SGXZ57979304.SGD","SG9999001176.USD","BK4550","BK4534","LU1894683348.USD","OZEM","BK4599","SG9999002224.SGD","BK4568","IE000M9KFDE8.USD","BK4007","LU0306806265.USD","PFE","IE00BBT3K403.USD","LU0289739699.SGD","LU0225284248.USD","LU0306807586.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","LU1057294990.SGD","IE00B3T34201.USD","LU0170899867.USD","LU1066051498.USD","SG9999001176.SGD","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","LU0321505868.SGD","LU1894683264.USD","SG9999013999.USD","BK4533","BK4581","SG9999002232.USD","BK4588","LU1883839398.USD","LU2596442595.SGD","BK4592","LU0321505439.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0234572021.USD","BK4585","IE0002270589.USD","LU1066053197.SGD","SG9999003800.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666416377","title":"Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666416377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666416377?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:35","pubTimestamp":1788899700,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slid 2.88% to $146.64 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.58% to 7,673.52 and Dow Jones Industrial Average  falling 1.18% to 52,786.07.This was the stock's second consecutive day of losses.Gilead Sciences Inc. closed 6.77% below its 52-week high of $157.29, which the company reached on February 11th.The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 2.22% to $269.12, Pfizer Inc.  fell 2.32% to $27.79, and Abbott Laboratories  fell 2.59% to $105.52.Trading volume  remained 673,543 below its 50-day average volume of 6.7 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 8, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","LU2357627491.SGD","SG9999015986.USD","LU1066051498.USD","BK4578","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1674673428.USD","SG9999015952.SGD","LU0965509010.AUD","LU0965509101.SGD","LU0058720904.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1934455277.USD","LU1430594728.SGD","LU2089984988.USD","LU1674673691.USD","LU0965509283.SGD","BK4568","LU0109394709.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","LU0122379950.USD","LU0823416689.USD","IBB","LU1057294990.SGD","LU0114720955.EUR","SG9999015945.SGD","LU0861579265.USD","LU1037948897.HKD","IE00BSNM7G36.USD","LU0234570918.USD","LU1778281490.HKD","BK4583","BK4550","LU2087621335.USD","LU2324357040.USD","IE00B19Z3581.USD","LU1023059063.AUD","BBH","MEDI","BK4588","LU1066053197.SGD","TBXU","LU1571399168.USD","BK4566","BMED","BK4139","LU0859254822.USD","BK4532","IBBQ","LU1037948541.HKD","IE00BKVL7J92.USD","BK4585","LU1934455194.USD","SG9999015978.USD","LU1061106388.HKD","IE00B3T34201.USD","BIB","LU0889565916.HKD","LU1585245621.USD","LU2112291526.USD","LU1839511570.USD","TMED","GILD","LU1934455863.HKD","LU0882574055.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377294","title":"Abbott Laboratories Stock Underperforms Tuesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377294","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377294?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:35","pubTimestamp":1788899700,"startTime":"0","endTime":"0","summary":"DJ Abbott Laboratories Stock Underperforms Tuesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Abbott Laboratories  slipped 2.59% to $105.52 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.58% to 7,673.52 and Dow Jones Industrial Average  falling 1.18% to 52,786.07.This was the stock's third consecutive day of losses.Abbott Laboratories closed 23.25% below its 52-week high of $137.49, which the company achieved on September 22nd.The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 2.22% to $269.12, Pfizer Inc.  fell 2.32% to $27.79, and Merck & Co. Inc.  fell 1.24% to $148.46.Trading volume  eclipsed its 50-day average volume of 10.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 8, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","LU0058720904.USD","LU0114720955.EUR","BK4568","LU2089984988.USD","BK4082","LU2133065610.SGD","LU0432979614.USD","LU0234572021.USD","IE0002141913.USD","LU1989763427.SGD","BK4533","IE00B4R5TH58.HKD","LU2468319806.SGD","LU0122379950.USD","LU1983299246.USD","LU1691799644.USD","LU0170899867.USD","LU0868494617.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU1914381329.SGD","SGXZ23171101.USD","LU1989763690.USD","BK4592","LU0211331839.USD","LU1057294990.SGD","LU2112291526.USD","SG9999002224.SGD","IHI","BK4585","IE00B2B36J28.USD","LU1721429741.USD","TMED","LU0208291251.USD","LU1061106388.HKD","LU2324357040.USD","BK4588","SGXZ41872573.SGD","LU1670628061.USD","LU0320765489.SGD","LU0882574055.USD","IE0009355771.USD","PJP","SG9999004303.SGD","LU1670627923.USD","SG9999002232.USD","LU1023059063.AUD","LU1721429402.USD","BK4566","BK4504","ABT","LU0070302665.USD","LU0266013472.USD","BK4581","IE00BJJMRZ35.SGD","LU2237957902.USD","IE00BJT1NW94.SGD","LU2237957811.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377330","title":"BioNTech CEO Ugur Sahin Sells Ordinary Shares Worth $7.86 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377330","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377330?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:11","pubTimestamp":1788898280,"startTime":"0","endTime":"0","summary":"BioNTech CEO Ugur Sahin sells ordinary shares worth $7.86 millionBioNTech CEO Ugur Sahin sold 76,500 ordinary shares on Sept. 3-4, 2026, trimming his stake to 781,709 shares.Sales priced at USD 102.85","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL70CBpk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech CEO Ugur Sahin Sells Ordinary Shares Worth $7.86 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4585","BK4568","BK4551","BK4588","BK4548","BK4139","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377856","title":"Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377856","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377856?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:08","pubTimestamp":1788898126,"startTime":"0","endTime":"0","summary":"Assembly Bio highlights Phase 2 starts for ABI-6250, GS-1179 in pipeline updateAssembly Biosciences outlined multiple Phase 2 starts across its portfolio in 2026 to early 2027, led by ABI-6250 in live","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL58BQBh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","LU2357627491.SGD","SG9999015986.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1674673428.USD","SG9999015952.SGD","LU0965509101.SGD","LU0058720904.USD","IE0002270589.USD","LU1934455277.USD","LU2089984988.USD","LU1674673691.USD","LU0965509283.SGD","BK4568","LU0109394709.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","ASMB","IBB","LU0861579265.USD","LU1037948897.HKD","IE00BSNM7G36.USD","LU0234570918.USD","LU1778281490.HKD","BK4583","LU2324357040.USD","LU1023059063.AUD","BBH","MEDI","BK4588","LU1066053197.SGD","TBXU","LU1571399168.USD","BK4566","BMED","LU1037948541.HKD","IBBQ","IE00BKVL7J92.USD","BK4585","SG9999015978.USD","IE00B3T34201.USD","BIB","LU0889565916.HKD","LU1585245621.USD","LU2112291526.USD","TMED","GILD","LU1934455863.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666437220","title":"Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666437220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666437220?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4XVZNR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","LU0114720955.EUR","LU2112291526.USD","SG9999015978.USD","IBB","LU1839511570.USD","BBH","LU1934455194.USD","TMED","LU1430594728.SGD","IE00BKVL7J92.USD","BK4532","BIB","IE00B19Z3B42.SGD","BK4568","LU0965509283.SGD","LU1571399168.USD","LU1585245621.USD","LU1934455277.USD","GILD","BMED","IE00B7SZLL34.SGD","LU0109394709.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU1037948897.HKD","LU1023059063.AUD","IBBQ","LU2324357040.USD","BK4588","IE00B3T34201.USD","LU1674673428.USD","LU2468319806.SGD","LU0965509101.SGD","LU1066053197.SGD","LU1934455863.HKD","BK4583","SG9999015952.SGD","LU0234570918.USD","LU0058720904.USD","ASMB","LU1066051498.USD","BK4550","TBXU","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU0882574055.USD","MEDI","LU2089984988.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372203","title":"Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372203?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4XVZNR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0859254822.USD","LU2468319806.SGD","TBXU","BK4588","ASMB","LU0234570918.USD","IE00BSNM7G36.USD","BK4532","IE0002270589.USD","LU0882574055.USD","BK4568","LU0965509010.AUD","LU2112291526.USD","LU0823416689.USD","BIB","IE00BKVL7J92.USD","LU1934455863.HKD","LU1037948897.HKD","LU1934455277.USD","LU2324357040.USD","LU1674673428.USD","TMED","GILD","IE00B19Z3B42.SGD","LU1066051498.USD","LU1674673691.USD","BK4550","LU1430594728.SGD","SG9999015986.USD","IBB","LU1571399168.USD","LU1934455194.USD","SG9999015978.USD","BMED","IBBQ","BBH","LU0965509283.SGD","MEDI","LU1037948541.HKD","LU2087621335.USD","LU1057294990.SGD","BK4139","LU1839511570.USD","LU2089984988.USD","LU0289739699.SGD","LU0320765992.SGD","LU0109394709.USD","LU0965508806.USD","BK4585","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666216372","title":"Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666216372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666216372?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4XVZNR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBBQ","LU1585245621.USD","IBB","LU2112291526.USD","LU2324357040.USD","BIB","MEDI","LU0882574055.USD","LU1674673428.USD","BK4578","GILD","LU1674673691.USD","SG9999015986.USD","LU1066053197.SGD","IE00BSNM7G36.USD","LU0109394709.USD","LU0861579265.USD","LU2468319806.SGD","LU0058720904.USD","LU1057294990.SGD","IE0002270589.USD","LU0122379950.USD","LU1934455277.USD","LU1430594728.SGD","SG9999015978.USD","LU1839511570.USD","LU0965509010.AUD","BK4139","LU0889565916.HKD","BK4532","TBXU","BK4550","LU0114720955.EUR","LU0965509283.SGD","LU0320765992.SGD","LU1934455863.HKD","ASMB","BK4583","TMED","SG9999015945.SGD","BMED","BK4585","BBH","BK4568","LU0859254822.USD","LU1037948897.HKD","LU1934455194.USD","BK4566","IE00BKVL7J92.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372326","title":"Moderately bullish activity in Moderna with shares down 1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372326?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:20","pubTimestamp":1788891611,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Moderna (MRNA), with shares down $2.60 near $142.95. Options volume relatively light with 44k contracts traded and c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNA","BK4585","BK4139","MRNX","MRNY","BK4534","BK4532","BK4568","BK4588","IDNA","WDNA","LGHT","GNOM","BK4501","BK4548","BK4551","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374571","title":"Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374571","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374571?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:15","pubTimestamp":1788887735,"startTime":"0","endTime":"0","summary":"• Gilead pulled back due to profit-taking following a sustained multi-month rally.\n• Strong second-quarter revenue was driven by flagship HIV and Trodelvy franchises.\n• Analysts maintain Buy ratings with an average price target of $157.79.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156548-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0122379950.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","BK4585","SG9999015952.SGD","IE00BKVL7J92.USD","LU0965509101.SGD","LU0889565916.HKD","BK4568","LU1585245621.USD","LU2112291526.USD","LU1037948897.HKD","LU0965509283.SGD","LU1934455194.USD","BK4583","IE00B19Z3581.USD","BBH","BK4532","BIB","GILD","TBXU","BK4588","LU1934455863.HKD","LU0114720955.EUR","LU0965509010.AUD","LU1061106388.HKD","LU1778281490.HKD","LU0823416689.USD","LU2089984988.USD","IBBQ","MEDI","LU0234570918.USD","BK4578","LU1839511570.USD","LU1066053197.SGD","LU1571399168.USD","LU2324357040.USD","LU0965508806.USD","LU1674673691.USD","LU1023059063.AUD","LU1430594728.SGD","LU0058720904.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","SG9999015986.USD","TMED","LU2087621335.USD","LU1934455277.USD","LU0109394709.USD","LU1037948541.HKD","LU0859254822.USD","LU1057294990.SGD","IE00B3T34201.USD","LU0289739699.SGD","LU0882574055.USD","LU1674673428.USD","LU2357627491.SGD","LU0320765992.SGD","IBB","BK4566","BK4550","LU2468319806.SGD","SG9999015978.USD","LU1066051498.USD","LU0861579265.USD","BMED","IE0002270589.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":2,"totalSize":233,"code":"91000000","status":"200"}]}}